Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer

Robert W. Veltri, M. Craig Miller, Gerard J. O'dowd, Alan Wayne Partin

Research output: Contribution to journalArticle

Abstract

Age-specific prostate-specific antigen (PSA) cutoffs were previously suggested and were found to miss significant cancers in older men. We assessed the influence of an age-adjusted PSA cutoff to optimize the diagnostic performance (sensitivity and specificity) of complexed PSA (cPSA) and total PSA (tPSA) in the differentiation of benign disease from prostate cancer using a contemporary referral patient cohort. The cPSA and tPSA values were determined using the Bayer Immuno 1 system. The diagnostic utility of tPSA and cPSA was assessed using a diverse contemporary test population consisting of sera prospectively collected between June 1999 and October 2000 from 3597 men who recently underwent a systematic biopsy by urologists in clinical practices throughout the United States. This contemporary patient sample had biopsy diagnoses of either no evidence of malignancy (NEM; n = 2189) or prostate cancer (n = 1408). All serum samples had tPSA values between 2.0 and 20.0 ng/mL. The mean tPSAs (ng/mL) for the NEM and prostate cancer groups were 7.1 ± 3.2 and 7.3 ± 3.3, respectively (P = 0.026). The mean cPSAs (ng/mL) for the NEM and prostate cancer groups were 5.6 ± 2.7 and 6.0 ± 2.9, respectively (P

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalUrology
Volume60
Issue number4 SUPPL.
DOIs
StatePublished - Oct 1 2002

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Referral and Consultation
Biopsy
Serum
Neoplasms
Sensitivity and Specificity
Population

ASJC Scopus subject areas

  • Urology

Cite this

Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. / Veltri, Robert W.; Miller, M. Craig; O'dowd, Gerard J.; Partin, Alan Wayne.

In: Urology, Vol. 60, No. 4 SUPPL., 01.10.2002, p. 47-52.

Research output: Contribution to journalArticle

Veltri, Robert W. ; Miller, M. Craig ; O'dowd, Gerard J. ; Partin, Alan Wayne. / Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. In: Urology. 2002 ; Vol. 60, No. 4 SUPPL. pp. 47-52.
@article{6406beae21b44eefbb86be16b3976b58,
title = "Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer",
abstract = "Age-specific prostate-specific antigen (PSA) cutoffs were previously suggested and were found to miss significant cancers in older men. We assessed the influence of an age-adjusted PSA cutoff to optimize the diagnostic performance (sensitivity and specificity) of complexed PSA (cPSA) and total PSA (tPSA) in the differentiation of benign disease from prostate cancer using a contemporary referral patient cohort. The cPSA and tPSA values were determined using the Bayer Immuno 1 system. The diagnostic utility of tPSA and cPSA was assessed using a diverse contemporary test population consisting of sera prospectively collected between June 1999 and October 2000 from 3597 men who recently underwent a systematic biopsy by urologists in clinical practices throughout the United States. This contemporary patient sample had biopsy diagnoses of either no evidence of malignancy (NEM; n = 2189) or prostate cancer (n = 1408). All serum samples had tPSA values between 2.0 and 20.0 ng/mL. The mean tPSAs (ng/mL) for the NEM and prostate cancer groups were 7.1 ± 3.2 and 7.3 ± 3.3, respectively (P = 0.026). The mean cPSAs (ng/mL) for the NEM and prostate cancer groups were 5.6 ± 2.7 and 6.0 ± 2.9, respectively (P",
author = "Veltri, {Robert W.} and Miller, {M. Craig} and O'dowd, {Gerard J.} and Partin, {Alan Wayne}",
year = "2002",
month = "10",
day = "1",
doi = "10.1016/S0090-4295(02)01695-3",
language = "English (US)",
volume = "60",
pages = "47--52",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer

AU - Veltri, Robert W.

AU - Miller, M. Craig

AU - O'dowd, Gerard J.

AU - Partin, Alan Wayne

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Age-specific prostate-specific antigen (PSA) cutoffs were previously suggested and were found to miss significant cancers in older men. We assessed the influence of an age-adjusted PSA cutoff to optimize the diagnostic performance (sensitivity and specificity) of complexed PSA (cPSA) and total PSA (tPSA) in the differentiation of benign disease from prostate cancer using a contemporary referral patient cohort. The cPSA and tPSA values were determined using the Bayer Immuno 1 system. The diagnostic utility of tPSA and cPSA was assessed using a diverse contemporary test population consisting of sera prospectively collected between June 1999 and October 2000 from 3597 men who recently underwent a systematic biopsy by urologists in clinical practices throughout the United States. This contemporary patient sample had biopsy diagnoses of either no evidence of malignancy (NEM; n = 2189) or prostate cancer (n = 1408). All serum samples had tPSA values between 2.0 and 20.0 ng/mL. The mean tPSAs (ng/mL) for the NEM and prostate cancer groups were 7.1 ± 3.2 and 7.3 ± 3.3, respectively (P = 0.026). The mean cPSAs (ng/mL) for the NEM and prostate cancer groups were 5.6 ± 2.7 and 6.0 ± 2.9, respectively (P

AB - Age-specific prostate-specific antigen (PSA) cutoffs were previously suggested and were found to miss significant cancers in older men. We assessed the influence of an age-adjusted PSA cutoff to optimize the diagnostic performance (sensitivity and specificity) of complexed PSA (cPSA) and total PSA (tPSA) in the differentiation of benign disease from prostate cancer using a contemporary referral patient cohort. The cPSA and tPSA values were determined using the Bayer Immuno 1 system. The diagnostic utility of tPSA and cPSA was assessed using a diverse contemporary test population consisting of sera prospectively collected between June 1999 and October 2000 from 3597 men who recently underwent a systematic biopsy by urologists in clinical practices throughout the United States. This contemporary patient sample had biopsy diagnoses of either no evidence of malignancy (NEM; n = 2189) or prostate cancer (n = 1408). All serum samples had tPSA values between 2.0 and 20.0 ng/mL. The mean tPSAs (ng/mL) for the NEM and prostate cancer groups were 7.1 ± 3.2 and 7.3 ± 3.3, respectively (P = 0.026). The mean cPSAs (ng/mL) for the NEM and prostate cancer groups were 5.6 ± 2.7 and 6.0 ± 2.9, respectively (P

UR - http://www.scopus.com/inward/record.url?scp=0036792052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036792052&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(02)01695-3

DO - 10.1016/S0090-4295(02)01695-3

M3 - Article

C2 - 12384163

AN - SCOPUS:0036792052

VL - 60

SP - 47

EP - 52

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4 SUPPL.

ER -